Skip to main content
Midas Edge

PROVECTUS BIOPHARMACEUTICALS INC

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

PVCT$0.04-17.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Changes in Stockholders’ Deficit

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024

Accumulated
Preferred Stock · Preferred Stock · Additional · Other
Series D · Series D-1 · Common Stock · Paid-In · Comprehensive · Accumulated
SharesAmountSharesAmountSharesAmountCapitalLossDeficitTotal
Balance at January 1, 202412,373,247$12,37310,361,097$10,361419,522,119$419,522$244,714,967$(60,165)$(252,690,409)$(7,593,351)
Conversion of 2021 Note to Series D-1 Preferred Stock--226,474226--647,935--648,161
Comprehensive loss:
Net loss--------(504,042)(504,042)
Other comprehensive loss-------(415)-(415)
Balance at March 31, 202412,373,247$12,37310,587,571$10,587419,522,119$419,522$245,362,902$(60,580)$(253,194,451)$(7,449,647)
Forfeited shares of Series D Preferred Stock(11,416,262)(11,416)----11,416---
Issuance of Series D-1 Preferred Stock for forfeited shares of Series D Preferred Stock--1,141,6261,141--(1,141)---
Conversion of 2021 Note to Series D-1 Preferred Stock--273,691275--783,021--783,296
Comprehensive Income (loss):
Net loss--------(846,848)(846,848)
Other comprehensive income-------126-126
Balance at June 30, 2024956,985$95712,002,888$12,003419,522,119$419,522$246,156,198$(60,454)$(254,041,299)$(7,513,073)
Conversion of 2022 Note to Series D-1 Preferred Stock--339,833339--972,261972,600
Conversion of accrued directors’ fees to Series D-1 Preferred Stock--744,878745--2,131,094--2,131,839
Conversion of Series D-1 Preferred Stock to Common Stock--(75,776)(75)757,760758(683)---
Comprehensive Income (loss):
Net loss--------(1,014,351)(1,014,351)
Other comprehensive income-------255-255
Balance at September 30, 2024956,985$95713,011,823$13,012420,279,879$420,280$249,258,870$(60,199)$(255,055,650)$(5,422,730)

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023

Accumulated
Preferred Stock · Preferred Stock · Additional · Other
Series D · Series D-1 · Common Stock · Paid-In · Comprehensive · Accumulated
SharesAmountSharesAmountSharesAmountCapitalLossDeficitTotal
Balance at January 1, 202312,373,247$12,3739,746,626$9,747419,497,119$419,497$242,954,193$(35,679)$(249,588,641)$(6,228,510)
Conversion of 2021 Note to Series D-1 Preferred Stock--18,87218--53,992--54,010
Comprehensive loss:
Net loss--------(827,454)(827,454)
Other comprehensive income-------191-191
Balance at March 31, 202312,373,24712,3739,765,4989,765419,497,119419,497243,008,185(35,488)(250,416,095)(7,001,763)
Conversion of 2021 Note to Series D-1 Preferred Stock--188,757189--540,033--540,222
Comprehensive loss:
Net loss--------(835,062)(835,062)
Other comprehensive loss-------(278)-(278)
Balance at June 30, 202312,373,247$12,3739,954,255$9,954419,497,119$419,497$243,548,218$(35,766)$(251,251,157)(7,296,881)
Common stock issued for services----25,000252,825--2,850
Conversion of 2021 Note to Series D-1 Preferred Stock--122,725122--351,110351,232
Conversion of 2022 Note to Series D-1 Preferred Stock--69,83870--199,805199,875
Comprehensive loss:
Net loss--------(775,839)(775,839)
Other comprehensive loss-------(441)-(441)
Balance at September 30, 202312,373,247$12,37310,146,818$10,146419,522,119$419,522$244,101,958$(36,207)$(252,026,996)$(7,519,204)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.